Targeting Sp1 transcription factor in prostate cancer therapy

Medicinal Chemistry

Volumn 7, Issue 5, 2011, Pages 518-525

  Sankpal, Umesh T ^a   Goodison, Steven ^a   Abdelrahim, Maen ^a   Basha, Riyaz ^a  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

Cancer therapy; Prostate cancer; PSA; Sp transcription factors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA INTEGRIN; ANDROGEN RECEPTOR; ARSENIC TRIOXIDE; ARTEMISININ; BETULIC ACID; BOSWELLIC ACID; FATTY ACID SYNTHASE; INTERSTITIAL COLLAGENASE; ISOTHIOCYANIC ACID DERIVATIVE; MITHRAMYCIN; POLYPHENOL DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; QUERCETIN; SCATTER FACTOR RECEPTOR; SELENIUM; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRANSCRIPTION FACTOR SP4; TRANSFORMING GROWTH FACTOR BETA;

AMINO TERMINAL SEQUENCE; APOPTOSIS; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA SEQUENCE; DRUG TARGETING; GENE CONTROL; GENE EXPRESSION REGULATION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN DNA BINDING; PROTEIN FUNCTION; REVIEW; TEA; TRANSACTIVATION; ZINC FINGER MOTIF;

ANIMALS; HUMANS; MALE; PROSTATIC NEOPLASMS; SP1 TRANSCRIPTION FACTOR;

EID: 80051975232     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/157340611796799203     Document Type: Review

References (102)

1. Latchman, D. S. Transcription factors: an overview. Int J Biochem Cell Biol 1997, 29, (12), 1305-12. (Pubitemid 28153484)
2. Babu, M. M.; Luscombe, N. M.; Aravind, L.; Gerstein, M.; Teichmann, S. A. Structure and evolution of transcriptional regulatory networks. Curr Opin Struct Biol 2004, 14, (3), 283-91. (Pubitemid 38749055)
3. Kadonaga, J. T.; Carner, K. R.; Masiarz, F. R.; Tjian, R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell 1987, 51, (6), 1079-90.
4. Kadonaga, J. T.; Courey, A. J.; Ladika, J.; Tjian, R. Distinct regions of Sp1 modulate DNA binding and transcriptional activation. Science 1988, 242, (4885), 1566-70.
5. Briggs, M. R.; Kadonaga, J. T.; Bell, S. P.; Tjian, R. Purification and biochemical characterization of the promoter-specific transcription factor, Sp1. Science 1986, 234, (4772), 47-52. (Pubitemid 17171544)
6. Courey, A. J.; Tjian, R. Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif. Cell 1988, 55, (5), 887-98.
7. Suske, G.; Bruford, E.; Philipsen, S. Mammalian SP/KLF transcription factors: bring in the family. Genomics 2005, 85, (5), 551-6. (Pubitemid 40463690)
8. Suske, G. The Sp-family of transcription factors. Gene 1999, 238, (2), 291-300. (Pubitemid 29446168)
9. Hagen, G.; Muller, S.; Beato, M.; Suske, G. Cloning by recognition site screening of two novel GT box binding proteins: a family of Sp1 related genes. Nucleic Acids Res 1992, 20, (21), 5519-25.
10. Kingsley, C.; Winoto, A. Cloning of GT box-binding proteins: a novel Sp1 multigene family regulating T-cell receptor gene expression. Mol Cell Biol 1992, 12, (10), 4251-61.
11. Waby, J. S.; Bingle, C. D.; Corfe, B. M. Post-translational control of sp-family transcription factors. Curr Genomics 2008, 9, (5), 301-11.
12. Philipsen, S.; Suske, G. A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Nucleic Acids Res 1999, 27, (15), 2991-3000. (Pubitemid 29355710)
13. Bouwman, P.; Philipsen, S. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol 2002, 195, (1-2), 27-38. (Pubitemid 35287159)
14. Birnbaum, M. J.; van Wijnen, A. J.; Odgren, P. R.; Last, T. J.; Suske, G.; Stein, G. S.; Stein, J. L. Sp1 trans-activation of cell cycle regulated promoters is selectively repressed by Sp3. Biochemistry 1995, 34, (50), 16503-8. (Pubitemid 26006497)
15. Hagen, G.; Muller, S.; Beato, M.; Suske, G. Sp1-mediated transcriptional activation is repressed by Sp3. EMBO J 1994, 13, (16), 3843-51. (Pubitemid 24275030)
16. Gartel, A. L.; Goufman, E.; Najmabadi, F.; Tyner, A. L. Sp1 and Sp3 activate p21 (WAF1/CIP1) gene transcription in the Caco-2 colon adenocarcinoma cell line. Oncogene 2000, 19, (45), 5182-8.
17. Dennig, J.; Beato, M.; Suske, G. An inhibitor domain in Sp3 regulates its glutamine-rich activation domains. EMBO J 1996, 15, (20), 5659-67. (Pubitemid 26385625)
18. Chen, J. L.; Attardi, L. D.; Verrijzer, C. P.; Yokomori, K.; Tjian, R. Assembly of recombinant TFIID reveals differential coactivator requirements for distinct transcriptional activators. Cell 1994, 79, (1), 93-105. (Pubitemid 24309516)
19. Furukawa, T.; Tanese, N. Assembly of partial TFIID complexes in mammalian cells reveals distinct activities associated with individual TATA box-binding protein-associated factors. J Biol Chem 2000, 275, (38), 29847-56. (Pubitemid 32043870)
20. Sadovsky, Y.; Webb, P.; Lopez, G.; Baxter, J. D.; Fitzpatrick, P. M.; Gizang-Ginsberg, E.; Cavailles, V.; Parker, M. G.; Kushner, P. J. Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein. Mol Cell Biol 1995, 15, (3), 1554-63.
21. Majello, B.; Napolitano, G.; De Luca, P.; Lania, L. Recruitment of human TBP selectively activates RNA polymerase II TATA-dependent promoters. J Biol Chem 1998, 273, (26), 16509-16. (Pubitemid 28311435)
22. Ryu, S.; Zhou, S.; Ladurner, A. G.; Tjian, R. The transcriptional cofactor complex CRSP is required for activity of the enhancerbinding protein Sp1. Nature 1999, 397, (6718), 446-50.
23. Ryu, S.; Tjian, R. Purification of transcription cofactor complex CRSP. Proc Natl Acad Sci U S A 1999, 96, (13), 7137-42. (Pubitemid 29299628)
24. Rachez, C.; Freedman, L. P. Mediator complexes and transcription. Curr Opin Cell Biol 2001, 13, (3), 274-80. (Pubitemid 32429491)
25. Naar, A. M.; Beaurang, P. A.; Zhou, S.; Abraham, S.; Solomon, W.; Tjian, R. Composite co-activator ARC mediates chromatindirected transcriptional activation. Nature 1999, 398, (6730), 828-32.
26. Soutoglou, E.; Viollet, B.; Vaxillaire, M.; Yaniv, M.; Pontoglio, M.; Talianidis, I. Transcription factor-dependent regulation of CBP and P/CAF histone acetyltransferase activity. EMBO J 2001, 20, (8), 1984-92. (Pubitemid 32397400)
27. Kadam, S.; Emerson, B. M. Transcriptional specificity of human SWI/SNF BRG1 and BRM chromatin remodeling complexes. Mol Cell 2003, 11, (2), 377-89. (Pubitemid 36293832)
28. Gartel, A. L.; Radhakrishnan, S. K. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005, 65, (10), 3980-5. (Pubitemid 40775632)
29. Song, J.; Ugai, H.; Kanazawa, I.; Sun, K.; Yokoyama, K. K. Independent repression of a GC-rich housekeeping gene by Sp1 and MAZ involves the same cis-elements. J Biol Chem 2001, 276, (23), 19897-904.
30. Won, J.; Yim, J.; Kim, T. K. Sp1 and Sp3 recruit histone deacetylase to repress transcription of human telomerase reverse transcriptase (hTERT) promoter in normal human somatic cells. J Biol Chem 2002, 277, (41), 38230-8. (Pubitemid 35154677)
31. Doetzlhofer, A.; Rotheneder, H.; Lagger, G.; Koranda, M.; Kurtev, V.; Brosch, G.; Wintersberger, E.; Seiser, C. Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol 1999, 19, (8), 5504-11. (Pubitemid 29339908)
32. Zhang, Y.; Dufau, M. L. Silencing of transcription of the human luteinizing hormone receptor gene by histone deacetylase-mSin3A complex. J Biol Chem 2002, 277, (36), 33431-8. (Pubitemid 34984866)
33. Chu, S.; Ferro, T. J. Sp1: regulation of gene expression by phosphorylation. Gene 2005, 348, 1-11. (Pubitemid 40410011)
34. Hung, J. J.; Wang, Y. T.; Chang, W. C. Sp1 deacetylation induced by phorbol ester recruits p300 to activate 12 (S)-lipoxygenase gene transcription. Mol Cell Biol 2006, 26, (5), 1770-85.
35. Yang, X.; Su, K.; Roos, M. D.; Chang, Q.; Paterson, A. J.; Kudlow, J. E. O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc Natl Acad Sci U S A 2001, 98, (12), 6611-6. (Pubitemid 32538264)
36. Spengler, M. L.; Guo, L. W.; Brattain, M. G. Phosphorylation mediates Sp1 coupled activities of proteolytic processing, desumoylation and degradation. Cell Cycle 2008, 7, (5), 623-30. (Pubitemid 351499001)
37. Tan, N. Y.; Khachigian, L. M. Sp1 phosphorylation and its regulation of gene transcription. Mol Cell Biol 2009, 29, (10), 2483-8.
38. Milanini-Mongiat, J.; Pouyssegur, J.; Pages, G. Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J Biol Chem 2002, 277, (23), 20631-9. (Pubitemid 34967366)
39. D'Addario, M.; Arora, P. D.; McCulloch, C. A. Role of p38 in stress activation of Sp1. Gene 2006, 379, 51-61. (Pubitemid 44247326)
40. Fojas de Borja, P.; Collins, N. K.; Du, P.; Azizkhan-Clifford, J.; Mudryj, M. Cyclin A-CDK phosphorylates Sp1 and enhances Sp1-mediated transcription. EMBO J 2001, 20, (20), 5737-47. (Pubitemid 33010050)
41. Marin, M.; Karis, A.; Visser, P.; Grosveld, F.; Philipsen, S. Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell 1997, 89, (4), 619-28. (Pubitemid 27511772)
42. Bouwman, P.; Gollner, H.; Elsasser, H. P.; Eckhoff, G.; Karis, A.; Grosveld, F.; Philipsen, S.; Suske, G. Transcription factor Sp3 is essential for post-natal survival and late tooth development. EMBO J 2000, 19, (4), 655-61. (Pubitemid 30093738)
43. Gollner, H.; Dani, C.; Phillips, B.; Philipsen, S.; Suske, G. Impaired ossification in mice lacking the transcription factor Sp3. Mech Dev 2001, 106, (1-2), 77-83. (Pubitemid 32701075)
44. van Loo, P. F.; Mahtab, E. A.; Wisse, L. J.; Hou, J.; Grosveld, F.; Suske, G.; Philipsen, S.; Gittenberger-de Groot, A. C. Transcription factor Sp3 knockout mice display serious cardiac malformations. Mol Cell Biol 2007, 27, (24), 8571-82.
45. Supp, D. M.; Witte, D. P.; Branford, W. W.; Smith, E. P.; Potter, S. S. Sp4, a member of the Sp1-family of zinc finger transcription factors, is required for normal murine growth, viability, and male fertility. Dev Biol 1996, 176, (2), 284-99. (Pubitemid 26202818)
46. St Amand, T. R.; Lu, J. T.; Zamora, M.; Gu, Y.; Stricker, J.; Hoshijima, M.; Epstein, J. A.; Ross, J. J., Jr.; Ruiz-Lozano, P.; Chien, K. R. Distinct roles of HF-1b/Sp4 in ventricular and neural crest cells lineages affect cardiac conduction system development. Dev Biol 2006, 291, (2), 208-17.
47. Shi, Q.; Le, X.; Abbruzzese, J. L.; Peng, Z.; Qian, C. N.; Tang, H.; Xiong, Q.; Wang, B.; Li, X. C.; Xie, K. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001, 61, (10), 4143-54. (Pubitemid 32720983)
48. Yao, J. C.; Wang, L.; Wei, D.; Gong, W.; Hassan, M.; Wu, T. T.; Mansfield, P.; Ajani, J.; Xie, K. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004, 10, (12 Pt 1), 4109-17. (Pubitemid 38812490)
49. Zannetti, A.; Del Vecchio, S.; Carriero, M. V.; Fonti, R.; Franco, P.; Botti, G.; D'Aiuto, G.; Stoppelli, M. P.; Salvatore, M. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 2000, 60, (6), 1546-51. (Pubitemid 30183423)
50. Chiefari, E.; Brunetti, A.; Arturi, F.; Bidart, J. M.; Russo, D.; Schlumberger, M.; Filetti, S. Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? BMC Cancer 2002, 2, 35.
51. Wang, L.; Wei, D.; Huang, S.; Peng, Z.; Le, X.; Wu, T. T.; Yao, J.; Ajani, J.; Xie, K. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 2003, 9, (17), 6371-80. (Pubitemid 38031822)
52. Wang, L.; Guan, X.; Gong, W.; Yao, J.; Peng, Z.; Wei, D.; Wu, T. T.; Huang, S.; Xie, K. Altered expression of transcription factor Sp1 critically impacts the angiogenic phenotype of human gastric cancer. Clin Exp Metastasis 2005, 22, (3), 205-13. (Pubitemid 41298002)
53. Faber, P. W.; King, A.; van Rooij, H. C.; Brinkmann, A. O.; de Both, N. J.; Trapman, J. The mouse androgen receptor. Functional analysis of the protein and characterization of the gene. Biochem J 1991, 278(Pt 1), 269-78.
54. Faber, P. W.; van Rooij, H. C.; van der Korput, H. A.; Baarends, W. M.; Brinkmann, A. O.; Grootegoed, J. A.; Trapman, J. Characterization of the human androgen receptor transcription unit. J Biol Chem 1991, 266, (17), 10743-9.
55. Gao, M.; Ossowski, L.; Ferrari, A. C. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgenindependent derivative. J Cell Physiol 1999, 179, (3), 336-46. (Pubitemid 29203158)
56. Wang, L. G.; Ossowski, L.; Ferrari, A. C. Androgen receptor level controlled by a suppressor complex lost in an androgenindependent prostate cancer cell line. Oncogene 2004, 23, (30), 5175-84. (Pubitemid 38980350)
57. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Van de Woude, G. F. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4, (12), 915-25. (Pubitemid 37493640)
58. Knudsen, B. S.; Edlund, M. Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res 2004, 91, 31-67. (Pubitemid 39140956)
59. Humphrey, P. A.; Zhu, X.; Zarnegar, R.; Swanson, P. E.; Ratliff, T. L.; Vollmer, R. T.; Day, M. L. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995, 147, (2), 386-96.
60. Verras, M.; Lee, J.; Xue, H.; Li, T. H.; Wang, Y.; Sun, Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 2007, 67, (3), 967-75.
61. Guo, Y.; Kyprianou, N. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res 1999, 59, (6), 1366-71. (Pubitemid 29136271)
62. Roberts, A. B.; Wakefield, L. M. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 2003, 100, (15), 8621-3. (Pubitemid 36899145)
63. Tu, W. H.; Thomas, T. Z.; Masumori, N.; Bhowmick, N. A.; Gorska, A. E.; Shyr, Y.; Kasper, S.; Case, T.; Roberts, R. L.; Shappell, S. B.; Moses, H. L.; Matusik, R. J. The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia 2003, 5, (3), 267-77. (Pubitemid 36754056)
64. Song, K.; Wang, H.; Krebs, T. L.; Kim, S. J.; Danielpour, D. Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II. Cancer Res 2008, 68, (19), 8173-82.
65. Pizer, E. S.; Lax, S. F.; Kuhajda, F. P.; Pasternack, G. R.; Kurman, R. J. Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors. Cancer 1998, 83, (3), 528-37. (Pubitemid 28354509)
66. Rossi, S.; Ou, W.; Tang, D.; Bhattacharya, N.; Dei Tos, A. P.; Fletcher, J. A.; Loda, M. Gastrointestinal stromal tumours overexpress fatty acid synthase. J Pathol 2006, 209, (3), 369-75. (Pubitemid 43997746)
67. Kuhajda, F. P. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000, 16, (3), 202-8. (Pubitemid 30114274)
68. Lu, S.; Archer, M. C. Sp1 coordinately regulates de novo lipogenesis and proliferation in cancer cells. Int J Cancer 2010, 126, (2), 416-25.
69. Crawford, E. D.; DeAntoni, E. P.; Ross, C. A. The role of prostatespecific antigen in the chemoprevention of prostate cancer. J Cell Biochem Suppl 1996, 25, 149-55. (Pubitemid 27078325)
70. Oesterling, J. E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991, 145, (5), 907-23.
71. Young, C. Y.; Montgomery, B. T.; Andrews, P. E.; Qui, S. D.; Bilhartz, D. L.; Tindall, D. J. Hormonal regulation of prostatespecific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 1991, 51, (14), 3748-52.
72. Montgomery, B. T.; Young, C. Y.; Bilhartz, D. L.; Andrews, P. E.; Prescott, J. L.; Thompson, N. F.; Tindall, D. J. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate 1992, 21, (1), 63-73.
73. Shin, T.; Sumiyoshi, H.; Matsuo, N.; Satoh, F.; Nomura, Y.; Mimata, H.; Yoshioka, H. Sp1 and Sp3 transcription factors upregulate the proximal promoter of the human prostate-specific antigen gene in prostate cancer cells. Arch Biochem Biophys 2005, 435, (2), 291-302. (Pubitemid 40222468)
74. Desgrosellier, J. S.; Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10, (1), 9-22.
75. Onishi, T.; Yamakawa, K.; Franco, O. E.; Kawamura, J.; Watanabe, M.; Shiraishi, T.; Kitazawa, S. Mitogen-activated protein kinase pathway is involved in alpha6 integrin gene expression in androgen-independent prostate cancer cells: role of proximal Sp1 consensus sequence. Biochim Biophys Acta 2001, 1538, (2-3), 218-27. (Pubitemid 32402244)
76. Wang, L. G.; Liu, X. M.; Chiao, J. W. Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate. Carcinogenesis 2006, 27, (10), 2124-32. (Pubitemid 44530587)
77. Yang, C. C.; Wang, Y. C.; Wei, S.; Lin, L. F.; Chen, C. S.; Lee, C. C.; Lin, C. C. Peroxisome proliferator-activated receptor gammaindependent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation. Cancer Res 2007, 67, (7), 3229-38. (Pubitemid 46724861)
78. Jutooru, I.; Chadalapaka, G.; Sreevalsan, S.; Lei, P.; Barhoumi, R.; Burghardt, R.; Safe, S. Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp Cell Res 2010, 316, (13), 2174-88.
79. Chun, J. Y.; Hu, Y.; Pinder, E.; Wu, J.; Li, F.; Gao, A. C. Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther 2007, 6, (9), 2572-80. (Pubitemid 47480423)
80. Husbeck, B.; Bhattacharyya, R. S.; Feldman, D.; Knox, S. J. Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action. Mol Cancer Ther 2006, 5, (8), 2078-85. (Pubitemid 44336580)
81. Hirpara, K. V.; Aggarwal, P.; Mukherjee, A. J.; Joshi, N.; Burman, A. C. Quercetin and its derivatives: synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability. Anticancer Agents Med Chem 2009, 9, (2), 138-61.
82. Deschner, E. E.; Ruperto, J.; Wong, G.; Newmark, H. L. Quercetin and rutin as inhibitors of azoxymethanol-induced colonic neoplasia. Carcinogenesis 1991, 12, (7), 1193-6.
83. Xing, N.; Chen, Y.; Mitchell, S. H.; Young, C. Y. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 2001, 22, (3), 409-14. (Pubitemid 32203819)
84. Yuan, H.; Gong, A.; Young, C. Y. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis 2005, 26, (4), 793-801. (Pubitemid 41214342)
85. Kim, Y. H.; Lee, D. H.; Jeong, J. H.; Guo, Z. S.; Lee, Y. J. Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem Pharmacol 2008, 75, (10), 1946-58.
86. Li, Y.; He, K.; Huang, Y.; Zheng, D.; Gao, C.; Cui, L.; Jin, Y. H. Betulin induces mitochondrial cytochrome c release associated apoptosis in human cancer cells. Mol Carcinog 2010, 49, (7), 630-40.
87. Kommera, H.; Kaluderovic, G. N.; Kalbitz, J.; Paschke, R. Lupane Triterpenoids-Betulin and Betulinic acid derivatives induce apoptosis in tumor cells. Invest New Drugs 2009.
88. Yogeeswari, P.; Sriram, D. Betulinic acid and its derivatives: a review on their biological properties. Curr Med Chem 2005, 12, (6), 657-66. (Pubitemid 40331058)
89. Chintharlapalli, S.; Papineni, S.; Ramaiah, S. K.; Safe, S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 2007, 67, (6), 2816-23. (Pubitemid 46548971)
90. Moussaieff, A.; Mechoulam, R. Boswellia resin: from religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials. J Pharm Pharmacol 2009, 61, (10), 1281-93.
91. Shah, B. A.; Qazi, G. N.; Taneja, S. C. Boswellic acids: a group of medicinally important compounds. Nat Prod Rep 2009, 26, (1), 72-89.
92. Yuan, H. Q.; Kong, F.; Wang, X. L.; Young, C. Y.; Hu, X. Y.; Lou, H. X. Inhibitory effect of acetyl-11-keto-beta-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. Biochem Pharmacol 2008, 75, (11), 2112-21.
93. Pang, X.; Yi, Z.; Zhang, X.; Sung, B.; Qu, W.; Lian, X.; Aggarwal, B. B.; Liu, M. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 2009, 69, (14), 5893-900.
94. Higgins, K. J.; Liu, S.; Abdelrahim, M.; Yoon, K.; Van der Laag, K.; Porter, W.; Metz, R. P.; Safe, S. Vascular endothelial growth factor receptor-2 expression is induced by 17beta-estradiol in ZR-75 breast cancer cells by estrogen receptor alpha/Sp proteins. Endocrinology 2006, 147, (7), 3285-95. (Pubitemid 43901119)
95. Ji, B. T.; Chow, W. H.; Hsing, A. W.; McLaughlin, J. K.; Dai, Q.; Gao, Y. T.; Blot, W. J.; Fraumeni, J. F., Jr. Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer 1997, 70, (3), 255-8. (Pubitemid 27099590)
96. Khan, N.; Mukhtar, H. Cancer and metastasis: prevention and treatment by green tea. Cancer Metastasis Rev 2010, 29, (3), 435-45.
97. Ren, F.; Zhang, S.; Mitchell, S. H.; Butler, R.; Young, C. Y. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 2000, 19, (15), 1924-32. (Pubitemid 30219035)
98. Firestone, G. L.; Sundar, S. N. Anticancer activities of artemisinin and its bioactive derivatives. Expert. Rev. Mol. Med., 2009, 11, e32.
99. Morrissey, C.; Gallis, B.; Solazzi, J. W.; Kim, B. J.; Gulati, R.; Vakar-Lopez, F.; Goodlett, D. R.; Vessella, R. L.; Sasaki, T. Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drugs 2010, 21, (4), 423-32.
100. Willoughby, J. A., Sr.; Sundar, S. N.; Cheung, M.; Tin, A. S.; Modiano, J.; Firestone, G. L. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J. Biol. Chem., 2009, 284, (4), 2203-13.
101. Wang, L. G.; Ferrari, A. C. Mithramycin Targets Sp1 and The Androgen Receptor Transcription Level: Potential Therapeutic Role in Advanced Prostate Cancer. Translational Oncogenomics, 2007, 2006, (TOG-1-Wang-et-al-(Longgui)), 0.
102. Choi, E. S.; Shim, J. H.; Jung, J. Y.; Kim, H. J.; Choi, K. H.; Shin, J. A.; Nam, J. S.; Cho, N. P.; Cho, S. D. Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1. Cancer Sci., 2011, 102, (4), 742-8.